Pranlukast
Completing data — refresh the page later to see the latest
Basic information
- CAS
103177-37-3- Standard SMILES
O=C(Nc1ccc2c(=O)cc(-c3nn[nH]n3)oc2c1)c1ccc(OCCCCc2ccccc2)cc1- Molecular formula
- C27H23N5O4
- Average molar mass
- 481.5 g/mol
Names & identifiers
- Preferred name
- Pranlukast
- English name
- Pranlukast
- Molecular formula
- C27H23N5O4
- Molecular weight
- 481.5
Names & synonyms
Ononrs411Ultairono1078PrenastPrandtlPranlukasONO-RS-411emihydratePRANLUKAST
Database identifiers
- CAS
103177-37-3- PubChem CID
- 115100
- ChEMBL
CHEMBL1085767
Properties
Physicochemical properties
- Melting point
- 236 · 236-238°C
- Density
- 1.374 · 1.374±0.06 g/cm3(Predicted)
- storage temp.
- -20 °C · Sealed in dry,Store in freezer, under -20°C
- solubility
- Soluble in DMSO (up to 25 mg/ml)
- pka
- 4.96 · 4.96±0.10(Predicted)
- form
- solid
- color
- White
- Merck
- 14 · 14,7710
- Stability
- 1 year · Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.
- InChIKey
- NBQKINXMPLXUET-UHFFFAOYSA-N
- SMILES
- C(NC1=C2OC(C3=NNN=N3)=CC(=O)C2=CC=C1)(=O)C1=CC=C(OCCCCC2=CC=CC=C2)C=C1
- CAS DataBase Reference
- 103177 · 103177-37-3(CAS DataBase Reference)
- FDA UNII
- 8 Z891092 · TB8Z891092
- ATC code
- 3 DC02 · R03DC02
- Symbol(GHS)
- 7 · GHS07
- Signal word
- Warning
- Hazard statements
- 315 · H315-H319-H413
- Precautionary statements
- 501 · P501-P273-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313
- Hazard Codes
- F,C
- Risk Statements
- 11 · 11-34
- Safety Statements
- 16 · 16-26-36/37/39-45
- RTECS
- 5647500 · CV5647500
- HS Code
- 2934.99 · 2934.99.4400
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
Safety data
- rtecs
- CV5647500
- hs_code
- 2934.99.4400
- Toxicity
- LD50 in male mice (mg/kg): >1000 i.v. (Toda)
- risk_code
- 11-34
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- hazard_code
- F,C
- safety_code
- 16-26-36/37/39-45
- Hazard statements
- H315-H319-H413
- Precautionary statements
- P501-P273-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313
Chemistry & industry
Applications
DescriptionPranlukast, a novel chromone derivative, was introduced in Japan for the treatment of bronchial asthma and allergic diseases. Pranlukast is a highly potent, selective and competitive antagonist of peptidoleukotrienes with high affinity for the LTD4 receptor. In patients with bronchial asthma, pranlukast was reported to induce significant improvement in both immediate and late asthmatic response induced by antigen. Pranlukast is also being evaluated clinically for the treatment of perennial allergic rhinitis, pediatric asthma, and cutaneous pruritus in dialysis patients. The therapeutic potential of pranlukast in managing irritable bowel syndrome has been suggested.
UsesA potent, selective and orally active CysLT receptor antagonist. Leukotriene antagonist. Used as an antiasthmatic
Usesantiasthmatic;leukotriene receptor-1 antagonist
UsesLabeled Pranlukast, intended for use as an internal standard for the quantification of Pranlukast by GC- or LC-mass spectrometry.
Upstream & downstream products
Upstream raw materials
Additional notes
DefinitionChEBI: N-[4-oxo-2-(2H-tetrazol-5-yl)-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamide is a member of chromones.
Suppliers
Loading…
Open inquiries
Loading…
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…